



Effects of Pemafibrate, a Novel Selective PPAR α Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Diabetes Care 2018;41:538–546 | <https://doi.org/10.2337/dc17-1589>

Eiichi Araki,¹ Shizuya Yamashita,^{2,3} Hidenori Arai,⁴ Koutaro Yokote,⁵ Jo Satoh,⁶ Toyoshi Inoguchi,⁷ Jiro Nakamura,⁸ Hiroshi Maegawa,⁹ Narihito Yoshioka,¹⁰ Yukio Tanizawa,¹¹ Hiroataka Watada,¹² Hideki Suganami,¹³ and Shun Ishibashi¹⁴

¹Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

²Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

³Rinku General Medical Center, Osaka, Japan

⁴National Center for Geriatrics and Gerontology, Aichi, Japan

⁵Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

⁶Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Miyagi, Japan

⁷Fukuoka Health Promotion Support Center, Fukuoka, Japan

⁸Division of Diabetes, Department of Internal Medicine, Aichi Medical University, Aichi, Japan

⁹Department of Medicine, Shiga University of Medical Science, Shiga, Japan

¹⁰Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center, NTT East Corporation, Hokkaido, Japan

¹¹Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

¹²Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan

¹³Clinical Data Science Department, Kowa Company, Ltd., Tokyo, Japan

¹⁴Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, Tochigi, Japan

Corresponding author: Eiichi Araki, earaki@gpo.kumamoto-u.ac.jp.

Received 1 August 2017 and accepted 27 November 2017.

Clinical trial reg. no. JapicCTI-142412, clinicaltrials.jp.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1589/-/DC1>.

© 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

OBJECTIVE

Type 2 diabetes is frequently complicated with atherogenic dyslipidemia. This study aimed to evaluate the efficacy and safety of pemafibrate (K-877) in patients with type 2 diabetes comorbid with hypertriglyceridemia.

RESEARCH DESIGN AND METHODS

Patients were randomly assigned to three groups and received placebo ($n = 57$), 0.2 mg/day pemafibrate ($n = 54$), or 0.4 mg/day pemafibrate ($n = 55$) for 24 weeks (treatment period 1). Subsequently, the patients received follow-up treatment for another 28 weeks (treatment period 2), in which the placebo was switched to 0.2 mg/day pemafibrate. This article presents the results of treatment period 1, which were the primary objectives.

RESULTS

The pemafibrate groups showed significantly reduced fasting serum triglyceride levels by ~45% compared with the placebo group ($P < 0.001$). Additionally, the pemafibrate groups displayed significant decreases in non-HDL and remnant lipoprotein cholesterol, apolipoprotein (Apo) B100, ApoB48, and ApoCIII levels and significant increases in HDL cholesterol and ApoA-I levels. LDL cholesterol levels were not considerably altered in the pemafibrate groups. Furthermore, the 0.2 mg/day pemafibrate group showed a significantly reduced HOMA–insulin resistance score compared with the placebo group; however, no significant changes compared with placebo were found in fasting plasma glucose, fasting insulin, glycoalbumin, or HbA_{1c} levels. The pemafibrate groups also showed significantly increased fibroblast growth factor 21 levels compared with the placebo group. All groups displayed comparable rates of adverse events and drug reactions.

CONCLUSIONS

Pemafibrate significantly ameliorated lipid abnormalities and was well tolerated in patients with type 2 diabetes comorbid with hypertriglyceridemia.

The leading cause of death in patients with type 2 diabetes is atherosclerotic cardiovascular disease (ASCVD) (1). Cardiovascular events are more common in patients with diabetes than in those without (2,3). The increased ASCVD risk in patients with diabetes is attributed to abnormalities in both glucose and lipid metabolism. Lipid abnormalities are often comorbid with type 2 diabetes and are unique in terms of quantitative and qualitative lipid abnormalities that are associated with insulin resistance (IR) (4). The clinical features of these abnormalities include elevated triglyceride (TG) levels, reduced HDL cholesterol (HDL-C) levels, and delayed TG-rich lipoprotein catabolism, leading to elevated postprandial TG levels, remnant lipoprotein accumulation, and increased small dense LDL production.

A number of large-scale clinical trials have demonstrated that the management of dyslipidemia resulted in significantly reduced cardiovascular risk in patients with diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) (5) and Cholesterol Treatment Trialists (CTT) Collaboration meta-analysis (6) reported that LDL cholesterol (LDL-C)-lowering therapy with statins reduces cardiovascular risk in patients with type 2 diabetes. Additionally, the Japan Diabetes Complications Study (JDCS) identified both high LDL-C and TG levels as risk factors for the development of coronary artery disease (7). Furthermore, the UK Prospective Diabetes Study (UKPDS) revealed that both high LDL-C and low HDL-C levels were associated with elevated coronary artery disease risk (8). Therefore, research in recent decades has focused on interventions targeting diabetic lipid abnormalities other than high LDL-C levels. In particular, large-scale clinical trials have revealed that treatment with fibrates, which decrease TG levels and increase HDL-C levels, reduces ASCVD risk in patients with type 2 diabetes. For example, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid studies, treatment with fenofibrate led to event reduction in subgroup patients with high TG and low HDL-C levels (9,10). Moreover, the post hoc analysis of the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) showed that treatment with gemfibrozil resulted in cardiovascular event reduction in a subgroup of patients with diabetes (11).

Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor α (PPAR α) modulator approved for the treatment of dyslipidemia. A dose-finding phase 2 trial on pemafibrate conducted in patients with atherogenic dyslipidemia revealed that this drug exerted significant TG reduction and HDL-C increase, with comparable rates of adverse events (AEs) to placebo, such as serum creatinine and liver enzyme increases, which suggests that pemafibrate may have a better benefit/risk balance than fenofibrate (12).

Given that type 2 diabetes is frequently complicated with atherogenic dyslipidemia, a considerable proportion of patients treated with pemafibrate are anticipated to have type 2 diabetes. However, to date, the efficacy and safety of pemafibrate, specifically in patients with type 2 diabetes comorbid with hypertriglyceridemia, have not been investigated through a prospective randomized trial. Therefore, we conducted this phase 3 clinical trial to evaluate them through placebo-controlled treatment for 24 weeks (treatment period 1), followed by further long-term treatment for another 28 weeks, in which placebo was switched to pemafibrate (treatment period 2). This article is based on the clinical study report for treatment period 1, which was documented before the completion of a 52-week treatment period. The overall results throughout the 52 weeks will be separately documented in another article based on the other clinical study report that includes the results of treatment period 2.

RESEARCH DESIGN AND METHODS

Study Design

This multicenter, placebo-controlled, randomized, double-blind, parallel-group study was performed in 34 medical institutions in Japan from 20 February 2014 to 30 April 2015, denoted as treatment period 1.

The study protocol was approved by the institutional review boards of the 34 medical institutions prior to the implementation of the study. Additional matters that needed to be approved, such as protocol amendments, were assessed and approved by the institutional review boards as needed. The study was conducted in accordance with the principles of the Declaration of Helsinki and the Ministerial Ordinance on Good Clinical Practice for Drugs issued by the Ministry of Health and Welfare, Japan. All

patients provided written informed consent prior to their participation. This study is registered at Japan Pharmaceutical Information Center Clinical Trials Information (JapicCTI-142412).

Patients

The inclusion criteria were as follows: 1) type 2 diabetes comorbid with hypertriglyceridemia ($\geq 6.2\%$ [44.3 mmol/mol] HbA_{1c} and ≥ 150 mg/dL [1.7 mmol/L] fasting serum TG levels for two consecutive screening visits); 2) age ≥ 20 years; 3) men and postmenopausal women; and 4) ≥ 12 weeks of dietary or exercise guidance before the first screening test.

The exclusion criteria were as follows: 1) fasting serum TG levels $> 1,000$ mg/dL (11.3 mmol/L); 2) type 1 diabetes, inadequately controlled diabetes ($\geq 8.0\%$ [63.9 mmol/mol] HbA_{1c}), diabetes requiring treatment with insulin, thiazolidinediones, biguanides, high-dose sulfonylureas (≥ 4 mg/day glimepiride, ≥ 7.5 mg/day glibenclamide, and ≥ 120 mg/day glipizide), sodium-glucose cotransporter 2 inhibitors, or combination therapy with three or more antidiabetic agents, and recent changes in the class and dosage of antidiabetic agents within 12 weeks prior to the first screening test; 3) inadequately controlled thyroid disorders; 4) inadequately controlled hypertension ($\geq 180/\geq 110$ mmHg systolic/diastolic blood pressure); 5) ≥ 1.5 mg/dL serum creatinine levels for patients receiving statin treatment; 6) a creatine kinase (CK) level that is more than five times the upper limit of normal (ULN) for patients on statin treatment; 7) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels that are more than three times the ULN, or serious hepatic disorders; 8) gallstones or serious biliary disorders; 9) occurrence of acute myocardial infarction or stroke within 3 months before providing informed consent; and 10) heart failure with New York Heart Association class III or IV.

Procedures

Patients who provided their informed consent were assessed for eligibility as participants (Supplementary Fig. 1). Eligible patients were randomly and equally assigned to the placebo, 0.2 mg/day pemafibrate (twice daily), and 0.4 mg/day pemafibrate (twice daily) groups using the dynamic allocation method with the HbA_{1c} value ($\geq 7.4\%$ [57.4 mmol/mol] or $< 7.4\%$) from the second screening test

and antidiabetic treatment (no agent, sulfonylurea, or the other antidiabetic agent) as adjustment factors. An independent third party generated the random allocation key codes, confirmed that placebo was indistinguishable from pemaifibrate, and conducted the numbering and concealment of the study drugs. Another independent third party managed the dynamic allocation based on the screening test results. Investigators and participants were not provided with any information related to the randomization throughout the study period.

Patients were instructed to take the assigned study drug twice daily before or after a meal (fixed throughout the study period) in the morning and evening for 24 weeks. Throughout the study period, the following drugs were prohibited for concomitant medications: fibrates, bile acid sequestrants, adrenocorticosteroids (systemic use), and sodium–glucose cotransporter 2 inhibitors. In principle, initiation, discontinuation, or change in the dosage regimen was prohibited for any antidiabetic agent not mentioned as prohibited concomitant medication from 4 weeks before the screening tests. Such changes in the use of antidiabetic agents, protease inhibitors, anabolic steroid hormones, and progestogen were prohibited. However, changes in the class and dosage regimen of antidiabetic agents were permitted for the next hospital visit (from week 16 onward) to treat deterioration in glycemic control found after week 12. Patients with a drinking habit were instructed to limit alcohol intake to <25 g/day during the treatment period.

The fasting blood and urine samples were collected at least 10 h after the last meal. Apolipoproteins (Apos) were measured through immunoassay. ApoB100 levels were calculated by subtracting ApoB48 from ApoB. LDL-C, HDL-C, and remnant lipoprotein cholesterol (RemL-C) levels were measured using the homogenous assays Determiner L LDL-C, MetaboLead HDL-C, and MetaboLead RemL-C (Kyowa Medex Co., Ltd., Tokyo, Japan), respectively. Fibroblast growth factor 21 (FGF21) was analyzed through an ELISA with Human FGF21 ELISA (BioVendor, Brno, Czech Republic). Common laboratory tests were performed using standardized methods at LSI Medience Corporation, Tokyo, Japan. High-performance liquid chromatography analyses (LipoSEARCH; Skylight Biotech Inc., Akita, Japan) were performed

after 12 weeks at Skylight Biotech to examine the lipoprotein profiles by subclass.

A meal tolerance test was performed at the study sites where this test was feasible at weeks 0 and 24 in patients who provided written informed consent for undergoing this test. Fasting blood samples were collected before the meal and study drug administration. The patients had the test meal within 15 min in principle and took the study drug at 30 min before or after starting the meal. Postprandial blood samples were collected 0.5, 1, 2, 2.5, 4.5, and 6.5 h after starting the meal. The test meal was Meal Test C (Saraya Co., Ltd., Osaka, Japan), which contained 592 kcal, 28.5 g fat (derived from butter), 75.0 g carbohydrates (derived from wheat starch and maltose), 8.0 g protein, 0.5–4.0 g dietary fiber, 125 mg sodium, and 0 g sucrose.

End Points

The primary efficacy end point was the percentage change in fasting serum TG level from the baseline at the final evaluation over 24 weeks. The secondary efficacy end points were the percentage changes or changes in the levels of fasting and postprandial lipid-related and glycemic parameters from baseline except for the primary efficacy end point.

The primary safety end points were the incidence rates of AEs and adverse drug reactions (ADRs) after the study drug administration. AEs were defined as any undesirable or unintended signs, symptoms, and disorders, including laboratory test abnormalities, regardless of their causal relationship with the study drug. AEs were regarded as ADRs if the causal relationship could not be ruled out.

Statistics

Pemaifibrate exposure in at least 100 patients for 1 year was needed to satisfy the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E1 guidelines for the evaluation of drug safety. Assuming that 10% of the patients would discontinue participation in the study, 55 patients per group was the aim for enrollment, considering that the power of the primary efficacy analysis was >99%.

The primary efficacy analysis was performed based on the full analysis set through a last-observation-carried-forward (LOCF) method, imputing the last valid values to subsequent missing

values. The safety analyses were based on the safety analysis set. The safety analysis set included all patients who received at least one dose of the study drug. The full analysis set included patients in the safety analysis set who had valid baseline and postbaseline efficacy measurements.

The primary efficacy analysis was conducted using ANCOVA with the baseline as a covariate. Multiplicity was adjusted using the Dunnett test for the comparison of the effect between the placebo group and each of the pemaifibrate groups. The secondary efficacy end points were analyzed using a one-sample *t* test for the differences from the baseline and ANCOVA for the differences between groups. The primary safety end points were analyzed using the Fisher exact test. The significance level was 0.05 for a two-sided test. SAS version 9.3 (SAS Institute, Inc., Cary, NC) was used for the analyses. All primary efficacy and safety end point analyses were performed based on a prespecified statistical analysis plan.

RESULTS

Supplementary Figure 2 shows the disposition of the patients. Among 306 patients who provided written consent, 167 patients were eligible and randomly assigned to the three groups. One patient discontinued participation in the study before study drug administration because of an AE. Thus, 57, 54, and 55 patients received the placebo, 0.2 mg/day pemaifibrate, and 0.4 mg/day pemaifibrate, respectively. After the study drug administration, the treatment was discontinued in six patients (two and four in the placebo and 0.4 mg/day pemaifibrate groups, respectively). Therefore, 160 patients completed the treatment for 24 weeks. Table 1 shows the characteristics of the patients. No noteworthy differences were observed between the groups. Men accounted for 72.9% of the patients, the mean age of the participants was 60.5 years, and their mean BMI was 25.9 kg/m². Approximately 60% of them had drinking habits, and two-thirds had hypertension or fatty liver. The mean duration of diabetes was 5.7 years, and 44.6% of the patients were receiving one or two antidiabetic agents, with dipeptidyl peptidase 4 inhibitor being the most frequently used drug (34.3%). Additionally, 39.2% of the patients received statins (atorvastatin 23.1%; pitavastatin 27.7%; rosuvastatin 35.4%; and other statins 13.8%).

Table 1—Patient characteristics

| | Placebo (n = 57) | Pemafibrate 0.2 mg/day (n = 54) | Pemafibrate 0.4 mg/day (n = 55) |
|---|------------------|---------------------------------|---------------------------------|
| Age (years) | 61.2 ± 10.0 | 59.8 ± 11.6 | 60.6 ± 10.1 |
| Age ≥65 years | 35.1 (20) | 35.2 (19) | 34.5 (19) |
| Men | 66.7 (38) | 79.6 (43) | 72.7 (40) |
| BMI (kg/m ²) | 26.0 ± 3.3 | 26.5 ± 3.8 | 25.3 ± 3.4 |
| BMI ≥25 kg/m ² | 57.9 (33) | 63.0 (34) | 45.5 (25) |
| Drinking habit | 57.9 (33) | 66.7 (36) | 58.2 (32) |
| Hypertension | 64.9 (37) | 59.3 (32) | 60.0 (33) |
| Fatty liver | 56.1 (32) | 59.3 (32) | 47.3 (26) |
| Duration of diabetes (years) | 5.5 ± 4.5 | 4.9 ± 3.7 | 6.8 ± 5.9 |
| No antidiabetic drug | 54.4 (31) | 55.6 (30) | 56.4 (31) |
| One antidiabetic drug | 22.8 (13) | 25.9 (14) | 23.6 (13) |
| Sulfonylurea | | 3.7 (2) | |
| DPP-4 inhibitor | 19.3 (11) | 18.5 (10) | 14.5 (8) |
| α-Glucosidase inhibitor | | | 5.5 (3) |
| Glinide | 3.5 (2) | 1.9 (1) | 1.8 (1) |
| GLP-1 receptor agonist | | 1.9 (1) | 1.8 (1) |
| Two antidiabetic drugs | 22.8 (13) | 18.5 (10) | 20.0 (11) |
| Sulfonylurea/DPP-4 inhibitor | 19.3 (11) | 11.1 (6) | 5.5 (3) |
| Sulfonylurea/α-glucosidase inhibitor | | | 3.6 (2) |
| Sulfonylurea/GLP-1 receptor agonist | | | 3.6 (2) |
| DPP-4 inhibitor/α-glucosidase inhibitor | 1.8 (1) | 3.7 (2) | 5.5 (3) |
| DPP-4 inhibitor/glinide | 1.8 (1) | | 1.8 (1) |
| α-Glucosidase inhibitor/glinide | | 3.7 (2) | |
| Statin | 40.4 (23) | 33.3 (18) | 43.6 (24) |
| TG (mmol/L) | 3.2 ± 1.3 | 2.7 ± 1.1 | 2.9 ± 1.1 |
| HDL-C (mmol/L) | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.3 ± 0.7 |
| HDL-C category <1.0 (mmol/L) | 28.1 (16) | 25.9 (14) | 20.0 (11) |
| FPG (mmol/L) | 7.7 ± 1.1 | 7.7 ± 1.1 | 7.4 ± 1.1 |
| Fasting insulin (pmol/L) | 92.7 ± 56.6 | 83.7 ± 49.2 | 81.1 ± 40.5 |
| HOMA-IR | 4.6 ± 3.0 | 4.2 ± 2.5 | 3.8 ± 1.8 |
| HbA _{1c} (%) | 7.0 ± 0.5 | 6.9 ± 0.4 | 7.0 ± 0.4 |
| HbA _{1c} (mmol/mol) | 52.9 ± 5.0 | 52.4 ± 4.7 | 52.6 ± 4.7 |
| Glycoalbumin (%) | 16.9 ± 2.5 | 17.1 ± 2.0 | 17.1 ± 2.2 |
| eGFR (mL/min/1.73 m ²) | 73.6 ± 19.2 | 75.7 ± 14.7 | 73.3 ± 14.4 |

Data are presented as the mean ± SD for continuous parameters and % (n) for categorical parameters. DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1.

Fasting serum TG levels in the placebo, 0.2 mg/day pemafibrate, and 0.4 mg/day pemafibrate groups decreased from 284.3 ± 117.6 mg/dL (3.2 ± 1.3 mmol/L), 240.3 ± 93.5 mg/dL (2.7 ± 1.1 mmol/L), and 260.4 ± 95.9 mg/dL (2.9 ± 1.1 mmol/L), respectively, at baseline to 242.0 ± 92.2 mg/dL (2.7 ± 1.0 mmol/L), 129.0 ± 71.5 mg/dL (1.5 ± 0.8 mmol/L), and 135.8 ± 71.2 mg/dL (1.5 ± 0.8 mmol/L) at week 24 (LOCF). The percentage changes in fasting serum TG levels at week 24 (LOCF) were −10.8% ($P < 0.01$), −44.3% ($P < 0.001$), and −45.1% ($P < 0.001$), respectively (Fig. 1A). Moreover, both of the pemafibrate groups had statistically significant reductions in these levels compared with the placebo group ($P < 0.001$, multiplicity adjusted). These findings were similar even without

imputation using the LOCF method. No sex differences were observed in the findings. In each pemafibrate group, TG was significantly reduced from week 4, and the significance remained until week 24 (Fig. 1B) ($P < 0.001$ for each point). The proportions of patients who achieved <150 mg/dL (1.7 mmol/L) fasting serum TG levels at week 24 (LOCF) were 15.8%, 81.5%, and 70.9% in the placebo, 0.2 mg/day pemafibrate, and 0.4 mg/day pemafibrate groups, respectively. The distances to this target level at week 24 (LOCF) were 92.0 ± 92.2 mg/dL (1.0 ± 1.0 mmol/L), −21.0 ± 71.5 mg/dL (−0.2 ± 0.8 mmol/L), and −14.2 ± 71.2 mg/dL (−0.2 ± 0.8 mmol/L), respectively.

With regard to other lipid-related parameters, the pemafibrate groups

showed significant reductions in non-HDL-C, RemL-C, ApoB100, ApoB48, and ApoCIII levels and significant increases in HDL-C and ApoA-I levels (Supplementary Fig. 3). LDL-C levels were not considerably altered in these groups. As a result of the high-performance liquid chromatography analyses conducted at week 12, the cholesterol content decreased in small and very small LDL, whereas it increased in large LDL in the pemafibrate groups (Supplementary Fig. 4). On the other hand, the cholesterol content increased in medium, small, and very small HDL, whereas it decreased in large HDL in these groups.

The changes in glycemic parameters were unclear (Fig. 2A–E). The 0.2 mg/day pemafibrate group showed a significant decrease in HOMA-IR score




Figure 1—Percentage change in fasting serum TGs from baseline to week 24 (LOCF) (A), with values presented as the least squares mean \pm SEM estimated using ANCOVA with baseline level as a covariate, and fasting serum TG levels over time (B), with values presented as the mean \pm SD. ** $P < 0.01$, *** $P < 0.001$ vs. baseline by ANCOVA. ††† $P < 0.001$ vs. placebo by ANCOVA with Dunnett test for multiplicity adjustment. Pema 0.2, pemaifibrate 0.2 mg/day; Pema 0.4, pemaifibrate 0.4 mg/day.

compared with the placebo group. However, no significant changes in other glycemic parameters were found between these groups. Both of the pemaifibrate groups showed a slight increase from the baseline in HbA_{1c} level at week 24, although this was not statistically significant when compared with the placebo group. The data were subjected to a post hoc repeated-measures ANCOVA at weeks 4–24, in which the pemaifibrate groups displayed significant reductions in fasting plasma glucose (FPG), fasting insulin, and HOMA-IR levels compared with the placebo group (Fig. 2F–H). FGF21 levels significantly increased in the pemaifibrate groups (Supplementary Fig. 5).

The results of the meal tolerance test showed that the pemaifibrate groups displayed a significantly reduced the area under the curve of 0–6.5 h for TG at week 24 compared with the placebo group, whereas the area under the curve of 0–6.5 h for plasma glucose and insulin were not significantly altered (Supplementary Fig. 6).

The incidence rates of AEs and ADRs were similar across the pemaifibrate and placebo groups without statistically significant differences (Table 2). Serious AEs were observed in three (5.3%), three (5.6%), and two (3.6%) patients, respectively, in the placebo, 0.2 mg/day pemaifibrate, and 0.4 mg/day pemaifibrate groups, and the causal relationship with the study treatment was ruled out for all groups. AEs leading to discontinuation of participation in the study were observed in four patients in the 0.4 mg/day pemaifibrate group, and a causal relationship

with acute kidney injury and liver function abnormality could not be ruled out. Abnormal elevations in levels of liver enzymes, serum creatinine, estimated glomerular filtration rate, and CK in the pemaifibrate groups were limited and comparable to those in the placebo group. The liver enzyme levels decreased, and the renal function test results and CK levels were not significantly altered with pemaifibrate treatment (Supplementary Table 1).

CONCLUSIONS

This study is the first to demonstrate the long-term efficacy and safety of pemaifibrate treatment for over 24 weeks in patients with type 2 diabetes comorbid with hypertriglyceridemia. Treatment with pemaifibrate for 24 weeks remarkably reduced the fasting serum TG levels by \sim 45%. The significant TG reduction was stably maintained over 24 weeks. The proportion of patients who achieved <150 mg/dL (1.7 mmol/L) TG levels at week 24 was $>80\%$ in the 0.2 mg/day pemaifibrate group but $\sim 70\%$ in the 0.4 mg/day pemaifibrate group. This finding may be attributed to the fact that the former group had lower baseline TG levels by ~ 20 mg/dL (0.2 mmol/L) than the latter group. Not only TG but also other markers of TG-rich lipoproteins were dramatically ameliorated. Additionally, HDL-C and ApoA-I levels increased. These changes were accompanied by favorable shifting in the LDL and HDL atherogenic profiles by subclasses. These comprehensive effects on lipoprotein profiles were similar to those observed in the previous studies including patients without diabetes

as well as the incidence rates of AEs and ADRs, which were similar across the treatment groups (12,13).

The unique quantitative and qualitative lipid abnormalities frequently comorbid with type 2 diabetes based on IR involve the following mechanisms. First, impaired insulin action enhances adipocyte lipolysis by activating hormone-sensitive lipase, thereby liberating nonesterified fatty acids (NEFAs) into the circulation. NEFA, which is taken up by the liver, is re-esterified to form TGs, thereby stimulating the secretion of VLDLs (4). Hyperinsulinemia secondary to IR is also suggested to increase de novo lipogenesis through augmenting the expression of carbohydrate responsiveness element-binding protein and sterol regulatory element-binding protein-1c (4). Second, Niemann-Pick C1-like 1 (NPC1L1) and microsomal TG transfer protein mRNA expression was enhanced in the small intestine, leading to the increases in chylomicron production and postprandial TG levels (14). Third, lipoprotein lipase (LPL) activity was impaired, and the catabolism of increased chylomicrons and VLDLs was delayed, leading to remnant lipoprotein accumulation, HDL-C reduction, and small, dense LDL production (4).

PPAR α agonists have been implicated to enhance hepatic NEFA uptake, NEFA β -oxidation, and concomitant decreases in de novo lipogenesis and VLDL production through which they modulate lipoprotein profiles (15). Pemaifibrate was also shown to enhance β -oxidation-related gene expression in human hepatocytes, murine hepatocytes, and rat livers (16,17) and decrease de novo lipid synthesis (18), hepatic TG content (17), and VLDL secretion in rat livers (18). PPAR α agonists are suggested to decrease intestinal cholesterol absorption, which may be mediated by decreases in NPC1L1, microsomal TG transfer protein, and ApoB mRNA (19,20). Pemaifibrate also inhibited NPC1L1 mRNA expression along with increased fecal cholesterol excretion in LDL receptor knockout mice (21) and inhibited ApoB mRNA expression in apoE2/E2 knockin mice (22). In the current study, the levels of ApoB48, a major component of chylomicrons, were significantly reduced with pemaifibrate treatment, which presumably reflects the reduction in intestine-derived chylomicron production and/or its stimulated catabolism. Furthermore, PPAR α agonists




Figure 2—Change from baseline to week 24 (LOCF) in FPG (A), fasting insulin (B), HOMA-IR (C), glycoalbumin (D), and HbA_{1c} (E), with values presented as the mean \pm SD, and the change from baseline to weeks 4–24 in FPG (F), fasting insulin (G), and HOMA-IR (H) estimated by post hoc repeated-measures ANCOVA for weeks 4–24, with values presented as the least squares mean \pm SEM. * P < 0.05, ** P < 0.01 vs. baseline by one-sample t test. † P < 0.05 vs. placebo by ANCOVA with baseline level as a covariate. ‡ P < 0.05, †† P < 0.01 vs. placebo by repeated-measures ANCOVA.

have been shown to increase the expression of LPL and inhibit that of ApoCIII, which inhibits LPL activity (15). Pema fibrate suppressed ApoC3 mRNA expression and enhanced postheparin plasma LPL activity in LDL receptor knockout mice (21). In fact, pema fibrate remarkably decreased the ApoCIII levels in the present and previous clinical studies. Through these mechanisms (i.e., suppressing the production and enhancing the catabolism of TG-rich lipoproteins), pema fibrate was suggested to increase levels of HDL-C and decrease levels of small, dense LDL, which has even higher atherogenicity (23).

The overall results of lipid profiles in the current study were similar to those

observed in a dose-response study of another PPAR α agonist, LY518674, comparing placebo and 200 mg/day fenofibrate (24). The baseline lipid profiles were similar in both studies, although only 14.6% of patients had diabetes in the latter study. The potential biphasic dose response of HDL-C increase and non-HDL-C reduction in the current study was similarly observed in the study of LY518674 (24). Such a dose response of HDL-C increase with LY518674 may be attributed to enhanced ApoA-I turnover, which was suggested by increased production and fractional catabolic rate of ApoA-I(25) and may be, at least in part, reflected to that of non-HDL-C reduction. ApoA-I turnover may be similarly enhanced

with pema fibrate also, considering that very large and large HDL-C levels decreased in the 0.4 mg/day pema fibrate group more than in the 0.2 mg/day pema fibrate group, whereas medium, small, and very small HDL-C levels increased in both groups in the current study. The same trend has been observed in previous studies (12,13).

The effects of pema fibrate on cardiovascular outcomes are being assessed in a global large-scale trial in patients with type 2 diabetes comorbid with atherogenic dyslipidemia (PROMINENT; clinical trial reg. no. NCT03071692) (26). The biphasic dose response, which was not clear in our knowledge, may be related to the fact that LY518674 and pema fibrate are both more potent and selective PPAR α agonists than fenofibrate (16,27). Pema fibrate is primarily eliminated via the liver, whereas fenofibrate and gemfibrozil are eliminated via kidneys (26,28). The above-mentioned differences may be, at least in part, associated with different responses in several clinical laboratory tests.

In the present and previous studies of pema fibrate compared with placebo and/or fenofibrate (12,13,29), the effects of pema fibrate on serum creatinine, ALT, γ -glutamyl transferase, and homocysteine levels appeared comparable to that of placebo or smaller than that of fenofibrate. Rather, pema fibrate even decreased the liver enzyme levels and affected the serum creatinine levels to a lesser extent than fenofibrate. Furthermore, these effects of pema fibrate monotherapy were similar to pema fibrate and statin combination therapy (13). Gemfibrozil shares similar adverse effects on the clinical laboratory tests and is associated with a relatively higher risk of rhabdomyolysis, which is even increased with statin combination therapy (28,30). In the study of LY518674 (24), the incidence rates of serum creatinine levels greater than the ULN and ALT levels $>1.5\times$ ULN were over three times higher in the 25–100 μ g/day LY518674 and 200 mg/day fenofibrate groups than in the placebo group, whereas both of them in the pema fibrate groups were comparable or lower than those in the placebo group from post hoc analyses in the current study using similar cutoff levels (Supplementary Table 2). The differences in the safety profiles supported a good risk/benefit balance of pema fibrate.

Table 2—Summary of AEs and ADRs

| | Placebo (n = 57) | Pemafibrate 0.2 mg/day (n = 54) | Pemafibrate 0.4 mg/day (n = 55) |
|------------------------------------|---------------------|------------------------------------|------------------------------------|
| Total AEs vs. placebo | 41 (71.9) | 36 (66.7) P = 0.681 | 33 (60.0) P = 0.232 |
| Serious AEs | 3 (5.3) | 3 (5.6) | 2 (3.6) |
| AEs leading to discontinuation | 0 | 0 | 4 (7.3) |
| Total ADRs vs. placebo | 7 (12.3) | 6 (11.1) P = 1.000 | 9 (16.4) P = 0.597 |
| Serious ADRs | 0 | 0 | 0 |
| ADRs leading to discontinuation | 0 | 0 | 2 (3.6) |
| Laboratory tests | | | |
| AST >3× ULN | 0 | 0 | 0 |
| AST >5× ULN | 0 | 0 | 0 |
| ALT >3× ULN | 1 (1.8) | 0 | 0 |
| ALT >5× ULN | 0 | 0 | 0 |
| GGT >3× ULN | 4 (7.0) | 2 (3.7) | 0 |
| GGT >5× ULN | 4 (7.0) | 0 | 0 |
| CK >4× ULN | 0 | 1 (1.9) | 0 |
| CK >5× ULN | 0 | 1 (1.9) | 0 |
| CK >10× ULN | 0 | 0 | 0 |
| Serum creatinine >1.5 mg/dL | 2 (3.5) | 1 (1.9) | 2 (3.6) |
| Serum creatinine >2.0 mg/dL | 0 | 1 (1.9) | 1 (1.8) |

Data are presented as the number of patients (%). GGT, γ -glutamyl transferase. *P* values were estimated by Fisher exact test.

In terms of glycemic parameters, the post hoc repeated-measures ANCOVA showed that pemafibrate decreased the fasting glucose, insulin, and HOMA-IR levels, although the prespecified analyses did not show a clear trend. The results of previous studies on the effects of PPAR α agonists other than pemafibrate on IR were inconsistent (31–35). Pemafibrate has been suggested to improve IR in the hyperinsulinemic-euglycemic-clamp study (36) and pooled analyses of previous studies (37). Moreover, markedly elevated FGF21 levels and reduced ApoCIII levels with pemafibrate treatment may positively impact the reduction of IR because an FGF21 analog ameliorated IR and glucose metabolism (38) and an ApoCIII antisense improved insulin sensitivity (39). The changes in fasting glycemic parameters were inconsistent with those in HbA_{1c} and glycoalbumin levels, which reflects the mean plasma glucose levels over the past 1–2 months and 2 weeks, respectively. Therefore, further investigation is needed to confirm the effects of pemafibrate on glucose metabolism.

The current study has the following limitations. First, it was not designed to investigate the effects of pemafibrate on

vascular events. The effects of PPAR α agonists on cardiovascular events in patients with type 2 diabetes were examined in the FIELD and ACCORD lipid studies (9,40). These studies demonstrated that cardiovascular events were significantly suppressed in the subgroup of patients with high TG and low HDL-C levels and suggested that diabetic microangiopathy might be prevented. Further large-scale studies on the effect of pemafibrate on diabetic complications and cardiovascular outcomes are necessary. Second, all patients were Japanese, many patients had relatively mild type 2 diabetes, many antidiabetic agents were prohibited, and changes in the class and dosage regimen of antidiabetic agents were restricted even for nonprohibited drugs. Therefore, further investigation is needed to clarify whether the findings of the current study can be generalized to other races or patients with more severe diabetes.

Conclusion

Pemafibrate, a novel selective PPAR α modulator, demonstrated excellent efficacy in the amelioration of lipid abnormalities and was well tolerated in patients with

type 2 diabetes. The good risk/benefit balance of pemafibrate was confirmed in this population, which was similar to that in previous studies in patients with hypertriglyceridemia with or without diabetes, over a long period of 24 weeks. These findings provide significant information on the management of lipid abnormalities in patients with type 2 diabetes comorbid with hypertriglyceridemia.

Acknowledgments. We acknowledge the investigators and patients who participated in this study (see APPENDIX).

Funding. This work was supported by Kowa Company, Ltd.

The study sponsor had a role in the study design, data collection, data analysis, data interpretation, and writing of the report.

Duality of Interest. E.A. reports receiving personal fees from Kowa during the conduct of the study as well as grants from Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Ono Pharmaceutical, Sanofi, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Novartis Pharma, Kowa Pharmaceutical, Astellas Pharma, AstraZeneca, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical, and Pfizer Japan and personal fees from MSD, Nippon Boehringer Ingelheim, Novo Nordisk Pharma, Ono Pharmaceutical, Sanofi, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Novartis Pharma, Kowa Pharmaceutical, Astellas Pharma, AstraZeneca, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical, and Eli Lilly Japan outside the submitted work. S.Y. reports receiving grants and personal fees from Kowa during the conduct of the study as well as grants from Nippon Boehringer Ingelheim, Otsuka Pharmaceutical, Shionogi, Bayer Yakuin National Institute of Biomedical Innovation, MSD, Japan Tobacco, Kyowa Medex, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Astellas Pharma, Daiichi Sankyo, Mochida Pharmaceutical, AstraZeneca, Izumisano City, Kaizuka City, Hayashibara, Teijin Pharma, Kaken Pharmaceutical, and Kissei Pharmaceutical and personal fees from Otsuka Pharmaceutical, Shionogi, Bayer Yakuin, MSD, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Ono Pharmaceutical, Astellas Pharma, Daiichi Sankyo, AstraZeneca, Medical Review, Skylight Biotech, Kaken Pharmaceutical, Pfizer Japan, Bristol-Myers Squibb, Amgen Astellas BioPharma, Sanofi, and Toa Eiyo outside the submitted work. In addition, S.Y. has a Fujirebio patent pending. H.A. reports receiving personal fees from Kowa during the conduct of the study as well as grants from Daiichi Sankyo and personal fees from Daiichi Sankyo, MSD, and Otsuka Pharmaceutical outside the submitted work. K.Y. reports personal fees from Kowa during the conduct of the study as well as grants from Astellas Pharma, Otsuka Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, and Bristol-Myers Squibb and personal fees from Astellas Pharma, AstraZeneca, Eisai, MSD, Ono Pharmaceutical, Kyowa Hakko Kirin, Kowa Pharmaceutical, Shionogi, Daiichi Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer Japan, and Mochida Pharmaceutical outside the submitted work. J.S. reports receiving personal fees from

Kowa during the conduct of the study as well as personal fees from Astellas Pharma, AstraZeneca, Nippon Boehringer Ingelheim, Eli Lilly Japan, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, MSD, Novo Nordisk Pharma, Ono Pharmaceutical, Pfizer Japan, Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical outside the submitted work. T.I. reports receiving personal fees from Kowa during the conduct of the study as well as grants from Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, Sanofi, Astellas Pharma, Kowa Pharmaceutical, AstraZeneca, Ono Pharmaceutical, Eli Lilly Japan, Sumitomo Dainippon Pharma, and MSD and personal fees from Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, Taisho Toyama Pharmaceutical, Sanofi, Astellas Pharma, Kowa Pharmaceutical, Novartis Pharma, AstraZeneca, Ono Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Kissei Pharmaceutical, Sumitomo Dainippon Pharma, and MSD outside the submitted work. J.N. reports receiving personal fees from Kowa during the conduct of the study. H.M. reports receiving personal fees from Kowa during the conduct of the study. N.Y. reports receiving personal fees from Kowa during the conduct of the study as well as personal fees from Novo Nordisk Pharma, Sanofi, and MSD outside the submitted work. Y.T. reports receiving personal fees from Kowa during the conduct of the study as well as grants from Astellas Pharma, MSD, Ono Pharmaceutical, Taisho Toyama Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Nippon Boehringer Ingerheim, Kyowa Hakko Kirin, Sanwa Kagaku Kenkyusho, Shionogi, Daiichi Sankyo, Pfizer Japan, Bristol-Myers Squibb, and Eli Lilly Japan and personal fees from Astellas Pharma, AstraZeneca, MSD, Ono Pharmaceutical, Kissei Pharmaceutical, Sanofi, Taisho Toyama Pharmaceutical, Sumitomo Dainippon Pharma, Takeda Pharma, Mitsubishi Tanabe Pharma, Boehringer Ingerheim Japan, and Novo Nordisk Pharmaceutical outside the submitted work. H.W. reports receiving personal fees from Kowa during the conduct of the study as well as grants from Astellas Pharma, Sanofi, Mitsubishi Tanabe Pharma, Novo Nordisk Pharma, AstraZeneca, Takeda Pharmaceutical, Novartis Pharma, Nippon Boehringer Ingelheim, MSD, Sumitomo Dainippon Pharma, Eli Lilly Japan, Sanwa Kagaku Kenkyusho, Ono Pharmaceutical, Kissei Pharmaceutical, and FUJIFILM Pharma outside the submitted work. H.S. is an employee of Kowa. S.I. reports receiving personal fees from Kowa during the conduct of the study as well as grants from Astellas Pharma, Daiichi Sankyo, Teijin Pharma, Takeda Pharmaceutical, Ono Pharmaceutical, Taisho Toyama Pharmaceutical, and Nippon Boehringer Ingelheim and personal fees from MSD, AstraZeneca, Sanwa Kagaku Kenkyusho, and Nippon Boehringer Ingelheim outside the submitted work.

Author Contributions. E.A. contributed to the concept, design, and execution of the study and

to the interpretation of the data and substantially contributed to writing and critically reviewing the manuscript. S.Y., H.A., K.Y., J.S., T.I., J.N., H.M., N.Y., Y.T., H.W., and S.I. contributed to the concept, design, and execution of the study; the interpretation of the data; and critical review of the manuscript. H.S. contributed to the concept, design, and execution of the study and to the interpretation of the data. H.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at The 59th Annual Meeting of the Japan Diabetes Society, Kyoto, Japan, 19–21 May 2016, and the 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany, 12–16 September 2016.

Appendix

The study sites and their principal investigators are as follows: NTT East Sapporo Hospital (So Nagai), Iwate Medical University Hospital (Noriko Takebe), Juntendo University Hospital (Fuki Ikeda), Aichi Medical University Hospital (J.N.), Shiga University of Medical Science Hospital (H.M.), Yamaguchi University Hospital (Yasuharu Ohta), Kyushu University Hospital (T.I.), Kumamoto University Hospital (Takeshi Matsumura), Chiba University Hospital (Minoru Takemoto), Sugiura Clinic (Toshiyuki Sugiura), Musashi Fujisawa Central Clinic (Seiki Wada), Nakayama Clinic (Mikihiro Nakayama), Goshi Hospital (Takeo Naito), Tao Internal Medicine Clinic (Tsuyoshi Tao), BOOCS Clinic Fukuoka (Kazuyuki Saito), Diabetes Center, Shin-Koga Hospital (Shoichi Akazawa and Eiji Kawasaki), Kurihara Diabetic Care Clinic (Yoshio Kurihara), Okuguchi Clinic of Internal Medicine (Fuminobu Okuguchi), Naka Kinen Clinic (Takeshi Osonoi), Tomonaga Clinic (Osamu Tomonaga), Kurashiki Central Hospital (Takashi Matsuoka), Kanauchi Medical Clinic (Rie Wada), Osaka Gyomeikan Hospital (Shinya Makino), Osaka Ekisaikai Hospital (Haruyuki Taguchi), Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, formerly NTT East Tohoku Hospital (Kazumi Yamato), Tokyo-Eki Center-Building Clinic (Arihiro Kiyosue), Sakakibara Sapia Tower Clinic (Makiko Abe), Chikamori Hospital (Yoshitaka Kumon), Ayame Medical Clinic (Hideo Ayame), Ehime Rosai Hospital (Kazuaki Nakai), Saiseikai Matsuyama Hospital (Hiroaki Miyaoka), Matsuyama Red Cross Hospital (Shiori Kondo), Matsuba Clinic (Ikuro Matsuba), and Manda Memorial Hospital (Shinji Taneda).

References

1. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. *N Engl J Med* 2015;373:1720–1732
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–234
3. Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the

General Practice Research Database. *Diabetologia* 2008;51:1639–1645

4. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? *Diabetologia* 2015;58:886–899

5. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004;364:685–696

6. Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008;371:117–125

7. Sone H, Tanaka S, Tanaka S, et al.; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDACS). *J Clin Endocrinol Metab* 2011;96:3448–3456

8. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). *BMJ* 1998;316:823–828

9. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563–1574

10. Scott R, O'Brien R, Fulcher G, et al.; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care* 2009;32:493–498

11. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). *Arch Intern Med* 2002;162:2597–2604

12. Ishibashi S, Yamashita S, Arai H, et al.; K-877-04 Study Group. Effects of K-877, a novel selective PPAR α modulator (SPPARM α), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. *Atherosclerosis* 2016;249:36–43

13. Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α), in combination with statin treatment: two randomised, double-blind, placebo-controlled trials in patients with dyslipidaemia. *Atherosclerosis* 2017;261:144–152

14. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. *Diabetologia* 2006;49:1008–1016

15. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* 1998;98:2088–2093

16. Raza-Iqbal S, Tanaka T, Anai M, et al. Transcriptome analysis of K-877 (a novel selective

- PPAR α modulator (SPPARM α)-regulated genes in primary human hepatocytes and the mouse liver. *J Atheroscler Thromb* 2015;22:754–772
17. Takei K, Han SI, Murayama Y, et al. The selective PPAR α modulator K-877 efficiently activates the PPAR α pathway and improves lipid metabolism in mice. *J Diabetes Investig* 2017;8:446–452
 18. Takizawa T, Inokuchi Y, Goto S, et al. The mechanism of K-877, a highly potent and selective ppar α modulator, on regulation of synthesis, secretion and metabolism of triglycerides and cholesterol (Abstract). *Circulation* 2013;128:A12867
 19. Jia L, Betters JL, Yu L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. *Annu Rev Physiol* 2011;73:239–259
 20. Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al. Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. *J Atheroscler Thromb* 2010;17:610–618
 21. Takei K, Nakagawa Y, Wang Y, et al. Effects of K-877, a novel selective PPAR α modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. *J Pharmacol Sci* 2017;133:214–222
 22. Hennuyer N, Duplan I, Paquet C, et al. The novel selective PPAR α modulator (SPPARM α) pemaifibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. *Atherosclerosis* 2016;249:200–208
 23. Hoogeveen RC, Gaubatz JW, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. *Arterioscler Thromb Vasc Biol* 2014;34:1069–1077
 24. Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR- α agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. *JAMA* 2007;297:1362–1373
 25. Millar JS, Duffy D, Gadi R, et al. Potent and selective PPAR- α agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2009;29:140–146
 26. Blair HA. Pemaifibrate: first global approval. *Drugs* 2017;77:1805–1810
 27. Singh JP, Kauffman R, Bensch W, et al. Identification of a novel selective peroxisome proliferator-activated receptor α agonist, 2-methyl-2-(4-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propylphenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. *Mol Pharmacol* 2005;68:763–768
 28. Wiggins BS, Saseen JJ, Page RL 2nd, et al.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2016;134:e468–e495
 29. Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemaifibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator (SPPARM α), in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. *J Clin Lipidol*. 27 October 2017 [Epub ahead of print]. <https://doi.org/10.1016/j.jacl.2017.10.006>
 30. Catapano AL, Graham I, De Backer G, et al.; Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis* 2016;253:281–344
 31. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)- α and PPAR- γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. *Diabetologia* 2007;50:1723–1731
 32. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. *Diabetes Care* 2013;36:2923–2930
 33. Black RN, Ennis CN, Young IS, Hunter SJ, Atkinson AB, Bell PM. The peroxisome proliferator-activated receptor α agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial. *J Diabetes Complications* 2014;28:323–327
 34. Shiochi H, Ohkura T, Fujioka Y, et al. Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study. *Diabetol Metab Syndr* 2014;6:113
 35. Taniguchi A, Fukushima M, Sakai M, et al. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. *Metabolism* 2001;50:477–480
 36. Matsuba I, Matsuba R, Ishibashi S, et al. The effects of selective PPAR α modulator, K-877, on the insulin sensitivity evaluated by glucose clamp test (Abstract). *J-Stage* 2016;59:S462 [in Japanese]
 37. Araki E, Ishibashi S, Yamashita S, et al. A highly potent and specific PPAR α agonist, K-877, improves lipid profiles and insulin sensitivity in dyslipidaemia subjects; an integrated analysis of 3 phase 2/3 trials (Abstract). *Diabetologia* 2014;57:S272
 38. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. *Cell Metab* 2013;18:333–340
 39. Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. *Diabetes Care* 2016;39:1408–1415
 40. Keech A, Simes RJ, Barter P, et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005;366:1849–1861